### 34: 18-7.37

## LEGISLATIVE HISTORY CHECKLIST Compiled by the NJ State Law Library

("New Jersey Biotechnology Financial Assistance)

NJSA:

34:1B-7.37

LAWS OF:

1995

CHAPTER:

137

BILL NO:

S812

SPONSOR(S):

Singer and McGreevey

DATE INTRODUCED:

March 10, 1994

COMMITTEE:

ASSEMBLY:

\_\_\_

..........

SENATE:

Natural Resources

AMENDED DURING PASSAGE:

Second reprint enacted

Yes

Amendments during passage denoted by superscript numbers

DATE OF PASSAGE:

ASSEMBLY:

January 23, 1995

Re-enacted 6-19-95

SENATE:

December 15, 1994

Re-enacted 5-11-95

DATE OF APPROVAL:

June 28, 1995

FOLLOWING STATEMENTS ARE ATTACHED IF AVAILABLE:

SPONSOR STATEMENT:

Yes

COMMITTEE STATEMENT:

ASSEMBLY:

No

SENATE:

Yes

FISCAL NOTE:

ИО

VETO MESSAGE:

Yes

MESSAGE ON SIGNING:

No

FOLLOWING WERE PRINTED:

REPORTS:

No

**HEARINGS:** 

Yes

974.90

New Jersey. Biotechnology Development Task Force.

I4 Meeting, held 11-16-93 and 10-8-93, Trenton, 1993.

1993

974.90 I42 New Jersey. Legislature. Joint Legislative Task Force on

Biotechnology.

1994a

Meetings held 4-11, 6-24, 8-9, 11-4, and 12-9-94. New

Jersey, 1994.

KBG:pp

# [SECOND REPRINT] SENATE, No. 812

### STATE OF NEW JERSEY

INTRODUCED MARCH 10, 1994

By Senators SINGER, McGREEVEY, Assemblymen Impreveduto and Felice

AN ACT to provide financial assistance for the development and commercialization of <sup>2</sup>emerging technology companies and<sup>2</sup> the biotechnology industry in the State and supplementing chapter 1B of Title 34 of the Revised Statutes.

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

- 1. This act shall be known and may be cited as the "New Jersey  $^2\underline{\text{Emerging Technology and}}^2$  Biotechnology Financial Assistance Act."
  - 2. The Legislature finds and declares that:
- a. Biotechnology is an emerging technology that holds great promise for designing living organisms that can be used for the treatment of diseases, and improvements to plants and animals, and to otherwise provide for exceptional advances for the betterment of living things;
- b. The development and support of biotechnology is especially important in light of the long-established pharmaceutical industry in the State, the many related university research programs on biotechnology, and the sizable investment, to date, of State funds in academic "centers of excellence," and is also vital to the fulfillment of certain responsibilities of the New Jersey Commission on Science and Technology;
- c. In order for society to appreciate the anticipated potential rewards from <sup>2</sup>emerging technology and <sup>2</sup> biotechnology research, private industry must have access to sufficient financial resources to conduct research and transfer research discoveries into viable, commercial products;
- d. As an emerging technology, biotechnology, the biotechnology industry, and the industry's required concomitant facilities face significant obstacles in obtaining financial assistance because of the perceived risk of investing in such new ventures;
- e. Because of the substantial employment opportunities that could be created by <sup>2</sup>[a]<sup>2</sup> successful <sup>2</sup>emerging technology and<sup>2</sup> biotechnology <sup>2</sup>[industry] industries<sup>2</sup> and the resulting importance of such <sup>2</sup>[industry] industries<sup>2</sup> to the State's economic base, the State can best stimulate and encourage private investment in <sup>2</sup>emerging technology and<sup>2</sup> biotechnology by directing the New Jersey Economic Development Authority to provide financial assistance to <sup>2</sup>emerging technology and<sup>2</sup> biotechnology companies located in the State.

EXPLANATION—Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted in the law.

<sup>2</sup>f. In considering how to best allocate its resources pursuant to this act, the authority should give due consideration to further supporting emerging technology or biotechnology joint ventures by providing economic development funds and assistance to help stimulate growth in disadvantaged urban areas of the State, where public/private partnerships have already been formed, or will be formed, to promote emerging technology and biotechnology research and product development initiatives.<sup>2</sup>

#### 3. As used in this act:

*7* 

"Authority" means the New Jersey Economic Development Authority established pursuant to section 4 of P.L.1974, c.80  $[C.34:1B-4]^{1}[.];^{1}$ 

"Biotechnology" means the <sup>1</sup>[use of living organisms to produce or modify products, improve plants or animals, or develop microorganisms for specific purposes.] continually expanding body of fundamental knowledge about the functioning of biological systems from the macro level to the molecular and sub-atomic levels, as well as novel products, services, technologies and sub-technologies developed as a result of insights gained from research advances which add to that body of fundamental knowledge; <sup>1</sup>

"Biotechnology company" means a person<sup>1</sup>, whose headquarters or base of operations is located in New Jersey, <sup>1</sup> engaged in the research, development, production, or provision of biotechnology for the purpose of developing or providing products or processes for specific commercial or public purposes, including but not limited to, medical, pharmaceutical, nutritional, and other health-related purposes, agricultural purposes, and environmental purposes, or a person<sup>1</sup>, whose headquarters or base of operations is located in New Jersey, <sup>1</sup> engaged in providing services or products necessary for such research, development, production, or provision<sup>1</sup>[.]; <sup>1</sup>

"Cost" means the expenses incurred in connection with the operation of  $^2$ [a] an emerging technology or  $^2$  biotechnology company in the State and shall include, but need not be limited to, the expenses of fixed assets,  $^2$ such as the construction, acquisition and development of real estate,  $^2$  materials, start-up, tenant fit-out, working capital, and any other expenses determined by the authority to be necessary to carry out the purposes of this act  $^1$ [.];  $^1$ 

<sup>2</sup>"Emerging Technology Company" means a person, whose headquarters or base of operations is located in New Jersey, and who employs some combination of the following: highly educated and/or trained managers and workers employed in New Jersey who use sophisticated scientific research service/production equipment, processes or knowledge to discover, develop, test, transfer or manufacture a product or service.<sup>2</sup>

<sup>1</sup>"Financial institution" means an individual or organization deemed eligible by the authority for participation in the program and shall include but need not be limited to, State-chartered or federally-chartered banks, savings banks or savings and loan associations, banks organized under the laws of a foreign government, private individuals, insurance companies, landlords, finance companies and venture capitalists; <sup>1</sup>

"Fixed assets" means any real property, interests in real property, plant, equipment, and any other assets commonly accepted as fixed assets  $^{1}[.];^{1}$ 

<sup>1</sup>["Participating bank" means a State- or federally-chartered bank, savings bank or savings and loan association, or a bank organized under the laws of a foreign government, deemed eligible by the authority for participation in the program.];<sup>1</sup>

"Program" means the "New Jersey <sup>2</sup>Emerging Technology and <sup>2</sup> Biotechnology Financial Assistance Program" established by the authority pursuant to section 4 of this act <sup>1</sup>[.]; and <sup>1</sup>

"Working capital" means those liquid capital assets other than fixed assets.

- 4. The authority shall establish a "New Jersey  $^2\underline{\text{Emerging}}$   $\underline{\text{Technology and}}^2$  Biotechnology Financial Assistance Program" to stimulate increased financing to help fund the costs incurred by new or expanding  $^2\underline{\text{emerging technology and}}^2$  biotechnology companies in the State.
- 5. a. To implement the program, the authority shall establish and maintain a special <sup>1</sup>[non-lapsing revolving fund] account <sup>1</sup> to be known as the "New Jersey <sup>2</sup>Emerging Technology and <sup>2</sup> Biotechnology Financial Assistance Fund," hereinafter "assistance fund," which shall be credited with: (1) an amount from the Economic Recovery Fund established pursuant to section 3 of P.L.1992, c.16 (C.34:1B-7.12) which the authority determines is necessary to effectively implement the program, within the limits of funding available from the Economic Recovery Fund; (2) any moneys that shall be received by the authority from the repayment of the moneys in the assistance fund used to provide financial assistance pursuant to this act and interest thereon; (3) other moneys of the authority, including but not limited to, any moneys available from other business assistance programs administered by the authority which it determines to deposit therein; and (4) any appropriation made by the Legislature to effectuate the purposes of this act.
- b. The authority shall use the moneys in the assistance fund to: (1) provide or participate in the provision of financial assistance to  $^2$ emerging technology or  $^2$  biotechnology companies deemed approved pursuant to section 6 of this act, which assistance may include, but need not be limited to, loan guarantees and assistance in establishing lines of credit,  $^2$ real estate development assistance,  $^2$  and technical advice on locating private and public sources of funding; and (2) defray the administrative expenses of the authority in carrying out the purposes and provisions of this act.
- c. The maximum amount and term of a loan, line of credit or other form of financial assistance made pursuant to this act shall be determined by the authority.
- d. Moneys in the assistance fund may be invested in such obligations as the authority may approve and net earnings received from the investment or deposit of moneys in the assistance fund by the authority shall be redeposited in the assistance fund for use for the purposes of this act.
- e. The authority shall establish sufficient reserves and liquid reserves to provide a sufficient and actuarially sound basis for its

pledges contained in any financial assistance agreement entered into pursuant to this act.

1

2

3

4

5

6

26

27

28

29

**30** 

31

32

33

34 35

36

37

38

39

40 41

42 43

44

45

46

47

48

49

50

51

52

53

54

- <sup>1</sup>f. The authority is authorized to disburse moneys in the assistance fund for purposes unrelated to this act if, for a period of at least three years, no moneys are disbursed from the assistance fund for the purposes set forth pursuant to this act. <sup>1</sup>
- 6. a. Applications for money from the assistance fund 7 established under this act shall be submitted by  $^2$ emerging 8 technology or<sup>2</sup> biotechnology companies in a form and manner 9 determined by the authority. 1[ The authority shall, in 10 consultation with the Department of Commerce and Economic 11 Development, the New Jersey Commission on Science and 12 13 Technology, and the Office of Labor Statistics in the Division of Planning and Research of the Department of Labor, develop 14 15 criteria for the approval or disapproval of applications. Such criteria shall include, but need not be limited to, an evaluation of 16 17 the applicant's actual or potential scientific and technological viability, and the extent to which the applicant's proposed or 18 expanded activities will enhance or diversify the State's capacity 19 and competitiveness in the field of biotechnology and increase 20 21 opportunities for permanent, full-time employment in the State. 22 The authority shall approve or disapprove applications pursuant to the criteria developed pursuant to subsection c. of this section, 23 and may employ any institution of higher education in this State 24 25 in the approval process. 1
  - b. The authority shall enter into written agreements with <sup>2</sup>emerging technology or <sup>2</sup> biotechnology companies approved for financial assistance pursuant to this act, and, as appropriate, with <sup>1</sup>[participating banks and other] <sup>1</sup> financial institutions <sup>1</sup>[,] <sup>1</sup> concerning the type, amount and terms of the financial assistance provided.
  - <sup>1</sup>c. The authority shall, in consultation with the Department of Commerce and Economic Development, the New Jersey Commission on Science and Technology and any institution of higher education in New Jersey, develop criteria for the approval or disapproval of applications submitted pursuant to subsection a. of this section. Such criteria shall include, but need not be limited to, an evaluation of the <sup>2</sup>emerging technology or <sup>2</sup> biotechnology company's actual or potential scientific and technological viability, a determination that the <sup>2</sup>emerging technology or biotechnology company's principal products or services are sufficiently innovative to provide a competitive advantage, a determination that the proposed financial assistance will result in significant growth in permanent, full-time employment in the State, a determination that the <sup>2</sup>emerging technology or biotechnology company has been unable to secure financial assistance on affordable terms from conventional sources, a determination that the financial assistance provided pursuant to this act demonstrates the prospect of a high rate of return on investment, and the extent to which the applicant's proposed or expanded activities will enhance or diversify the State's capacity and competitiveness in the field of <sup>2</sup>emerging technology or biotechnology. 1
    - <sup>2</sup>d. The Department of Commerce and Economic Development

and the authority may promote economic development in disadvantaged urban areas of the State, where emerging technology or biotechnology joint ventures have been or will be established.<sup>2</sup>

- 7. Not later than one year following the effective date of this act, and for each succeeding year in which a financial assistance agreement entered into under this act is in effect, the authority shall prepare a report on the program. The report shall include, but need not be limited to, a description of the demand for the program from <sup>2</sup>emerging technology and<sup>2</sup> biotechnology companies and <sup>1</sup>[participating banks] financial institutions<sup>1</sup>, the efforts made by the authority to promote the program, the total amount of financial assistance approved by the authority pursuant to the program and an assessment of the effectiveness of the program in meeting the goals of this act. The authority shall submit its report to the Governor and the Legislature, including therein any recommendations for legislation to improve the effectiveness of the program.
- 8. The authority shall adopt, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), any rules and regulations necessary to effectuate the purposes of this act. In developing procedures and forms to be used in connection with the application for and approval of financial assistance pursuant to this act, the authority shall consider the special needs and problems of <sup>2</sup>emerging technology and <sup>2</sup> biotechnology companies in the State.
  - 9. This act shall take effect immediately.

Directs EDA to establish financial assistance program for emerging technology and biotechnology industries.

9. This act shall take effect immediately.

### STATEMENT

This bill directs the New Jersey Economic Development Authority (EDA) to establish a financial assistance program to assist the development and commercialization of the biotechnology industry in the State. Such a financial assistance program is essential if private industry is to translate biotechnology discoveries into meaningful products for the treatment of diseases, improvements to plants and animals, and other exceptional advances for the betterment of living things.

Biotechnology is an emerging technology that designs living organisms which can be used to achieve specific purposes. However, because of the perceived investment risks associated with "cutting edge" technology, biotechnology entrepreneurs in New Jersey are currently having great difficulty arranging for financial assistance. Without this assistance, these entrepreneurs can not pay the varied costs necessarily incurred in the start-up, development, and commercialization of biotechnology products.

Since the biotechnology industry is a potentially significant generator of new jobs, and since other states are aware of this potential and are actively involved in promoting the development of the biotechnology industry in their states, it is vital that New Jersey compete for this industry or risk losing an important economic benefit. Therefore, New Jersey can best assist itself and the biotechnology industry in our State by directing the EDA to use its financial expertise to help secure financial assistance for the emerging needs of the biotechnology industry.

Directs Economic Development Authority to establish financial assistance program for biotechnology industry.

## SENATE NATURAL RESOURCES, TRADE AND ECONOMIC DEVELOPMENT COMMITTEE

STATEMENT TO

### SENATE, No. 812

with committee amendments

### STATE OF NEW JERSEY

DATED: JUNE 16, 1994

The Senate Natural Resources, Trade and Economic Development Committee favorably reports Senate Bill No. 812, with Senate committee amendments.

This bill directs the New Jersey Economic Development Authority (EDA) to establish a financial assistance program to assist the development and commercialization of the biotechnology industry in the State. Such a financial assistance program is essential if private industry is to translate biotechnology discoveries into meaningful products for the treatment of diseases, improvements to plants and animals, and other exceptional advances for the betterment of living things.

Biotechnology is an emerging technology that designs living organisms which can be used to achieve specific purposes. Some of these purposes include medical, pharmaceutical, agricultural and environmental remediation. Environmental applications include the development of safe and environmentally sound processes for the removal of toxics from dredge spoils and contaminants from hazardous waste sites, and the development of environmentally sound manufacturing and production systems.

Because of the perceived investment risks associated with "cutting edge" technology, biotechnology entrepreneurs in New Jersey are currently having great difficulty arranging for financial assistance. Without this assistance, these entrepreneurs can not pay the varied costs necessarily incurred in the start-up, development, and commercialization of biotechnology products.

The committee amendments broaden the definition of biotechnology to mean the "continually expanding body of fundamental knowledge about the functioning of biological systems," as well as the products, services and technologies developed from this knowledge. The original definition included only the use of living organisms to produce or modify products, improve plants or animals, or to develop microorganisms for specific purposes.

Other definitional changes limit eligibility for financial assistance only to those biotechnology firms whose headquarters and base of operations are located in New Jersey, and expand the list of eligible lenders under the program to insurance companies, private individuals, venture capitalists and others.

The committee amendments would also authorize the EDA to employ the New Jersey Commission on Science and Technology or any institution of higher education in the State to assist in its approval or disapproval of an application for financial assistance. The amendments also authorize the EDA to enlist the assistance of these organizations in the development of general criteria for the approval or disapproval of applications for assistance.

The committee also amended the bill to define further the eligibility requirements of applicants. These requirements include determinations that: (1) the principal products or services are sufficiently innovative so as to provide a competitive advantage; (2) financial assistance will result in significant employment growth and a high rate of return on investment; and, (3) the applicant has been unable to secure required capital from conventional sources.

Other amendments included in the bill are technical in nature or serve to align the bill's goals with existing EDA assistance program practices.

## SENATE BILL NO. 812 (First Reprint)

To the Senate:

Pursuant to Article V, Section I, Paragraph 14 of the New Jersey Constitution, I am returning Senate Bill No. 812 (First Reprint) with my objections for reconsideration.

#### A. Summary of Bill

This bill directs the New Jersey Economic Development

Authority (EDA) to establish a financial assistance program to

stimulate increased financing and to help fund the costs incurred

by new or expanding biotechnology companies in this State. In

implementing this program, the EDA may provide loan guarantees,

assistance in establishing lines of credit, technical advice on

locating private and public sources of funding, and any other

assistance it deems appropriate. The EDA is required to adopt

rules and regulations to effectuate the purposes of this bill.

### B. Recommended Action

This bill recognizes the importance of emerging technologies to our State's economy by making available necessary financial assistance to the biotechnology industry in the State of New Jersey. I commend the Legislature and the bill's sponsors for their efforts.

I am advised that one of the reasons this program is needed is that biotechnology entrepreneurs are sometimes faced with difficulty in obtaining financial assistance due to the perceived investment risks associated with "cutting edge" technology.

Because other emerging technology companies also engage in high risk and costly research and development efforts and are subject to the same financing obstacles, I recommend that the financial assistance program established by this bill be expanded to

## STATE OF No V JERSEY EXECUTIVE DEPARTMENT

2

include "emerging technology companies" in order to maximize the benefits of this program.

Moreover, one of the biggest impediments to the growth of the biotechnology industry in this State identified by the joint legislative Biotechnology Development Task Force was the lack of available research facilities. As currently written, this bill only indirectly addresses facilities requirements through the definition of fixed assets. I therefore recommend that the bill be clarified to include the construction, acquisition and development of real estate as an eligible program expense.

Additionally, I believe it is appropriate to authorize the EDA, under the umbrella of the Department of Commerce and Economic Development, to provide funds to stimulate the economic development of disadvantaged urban areas.

For these reasons, I herewith return Senate Bill. No. 812 (First Reprint) and recommend that it be amended as follows:

Page 1. Title. Line 2:

	<pre>"emerging technology companies and"</pre>
Page 1, Section 1, Line 9:	After "Jersey" insert "Emerging Technology and"
Page 1, Section 2, Line 24:	After "from" insert "emerging technology and"
Page 1, Section 2, Line 33:	Delete "a"; after "successful" insert

After "of" insert

Delete "a"; after
"successful" insert
"emerging technology
and"; delete "industry"
and insert "industries"

Page 1, Section 2, Line 34:

Delete "industry" and insert "industries"

Page 1, Section 2, Line 36: After "in" insert "emerging technology and"

Page 1, Section 2, Line 38: After "to" insert "emerging technology and"

Page 1, Section 2, Line 39:

In considering how to best allocate its resources pursuant to this act, the authority

should give due consideration to further supporting emerging technology or biotechnology joint ventures by providing economic development funds and assistance to help stimulate growth in disadvantaged urban areas of the State, where public/private partnerships have already been formed, or will be formed, to promote emerging technology and biotechnology research and product development initiatives."

Page 2, Section 3, Line 22:

After "of" delete "a" and insert "an emerging technology or"

Page 2, Section 3, Line 23:

After "assets," insert
"such as the
construction, acquisition
and development of real
estate,"

Page 2, Section 3, Line 27:

Insert new definition: "'Emerging Technology Company' means a person, whose headquarters or base of operations is located in New Jersey, and who employs some combination of the following: highly educated and/or trained managers and workers employed in New Jersey who use sophisticated scientific research service/production equipment, processes or knowledge to discover, develop, test, transfer or manufacture a product or service."

Page 2. Section 3. Line 41:

After "New Jersey" insert "Emerging Technology and"

Page 2, Section 4, Line 46:

After "New Jersey" insert "Emerging Technology and"

Page 2, Section 4, Line 48:

After "expanding" insert "emerging technology and"

Page 2, Section 5, Line 52:

After "New Jersey" insert "Emerging Technology and"

Page 3, Section 5, Lines 13-14:

After "assistance to" insert "emerging technology or"

Page 3, Section 5, Line 17:

After "credit," insert "real estate development assistance,"

## STATE OF NEW JERSEY Executive Department

4

Page 3, Section 6, Line 38: After "by" insert "emerging technology or"

Page 4. Section 6. Line 2: After "with" insert "emerging technology or"

Page 4. Section 6. Line 13: After "the" insert "emerging technology or"

Page 4, Section 6, Line 15: After "the" insert "emerging technology or"

Page 4. Section 6. Line 20: After "the" insert "emerging technology or"

Page 4, Section 6, Line 26: After "of" insert

"emerging technology or"

Insert new section "d. The Department of Commerce and Economic Development and the authority may promote economic development in disadvantaged urban areas of the State, where emerging technology or biotechnology joint ventures have been or will be established."

Page 4, Section 7, Line 33: After "from" insert

"emerging technology and"

Page 4, Section 7, Line 48: After "of" insert

"emerging technology and"

Respectfully,

/s/ Christine Todd Whitman

GOVERNOR

[seal]

Attest:

/s/ Margaret M. Foti

Chief Counsel to the Governor

Page 4. Section 6. Line 27: